MWA
PRQR icon

Medallion Wealth Advisors’s ProQR Therapeutics PRQR Stock Holding History

Medallion Wealth Advisors’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19 Hold
10
– – ﹤0.01% 1209
2026
Q1 		$16 Hold
10
– – ﹤0.01% 1117
2025
Q4 		$20 Hold
10
– – ﹤0.01% 1112
2025
Q3 		$21 Hold
10
– – ﹤0.01% 1098
2025
Q2 		$20 Hold
10
– – ﹤0.01% 1090
2025
Q1 		$13 Hold
10
– – ﹤0.01% 1068
2024
Q4 		$27 Buy
+10
New +$32 ﹤0.01% 1010

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Medallion Wealth Advisors's PRQR Position: Q2 2026 in Review

Medallion Wealth Advisors held its ProQR Therapeutics (PRQR) position steady in Q2 2026 at 10 shares worth $19. The position accounts for ﹤0.01% of the portfolio, ranked #1209.

Medallion Wealth Advisors first reported a position in PRQR in Q4 2024 and has held it in 7 quarters since. The position peaked at $27 in Q4 2024. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • Medallion Wealth Advisors held 10 shares of ProQR Therapeutics worth $19 as of Q2 2026.
  • Medallion Wealth Advisors left its ProQR Therapeutics share count unchanged in Q2 2026.
  • ProQR Therapeutics made up ﹤0.01% of Medallion Wealth Advisors's portfolio in Q2 2026, its #1209 holding.
  • Medallion Wealth Advisors first reported a position in ProQR Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Medallion Wealth Advisors's ProQR Therapeutics position peaked at $27 in Q4 2024.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Medallion Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.